Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shikama, N.
Right arrow Articles by Ishii, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shikama, N.
Right arrow Articles by Ishii, K.

Radiology, Vol 204, 467-470, Copyright © 1997 by Radiological Society of North America

ARTICLES

Clinical stage IE primary lymphoma of the nasal cavity: radiation therapy and chemotherapy

N Shikama, I Izuno, M Oguchi, K Gomi, S Sone, K Takei, S Sasaki, T Wako, N Itou and K Ishii
Department of Radiology, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.

PURPOSE: To determine the appropriate radiation therapy and chemotherapy for primary lymphoma of the nasal cavity to improve the local control and survival rates. MATERIALS AND METHODS: Of the 25 adult patients with stage IE nasal lymphoma, nine underwent local radiation therapy alone and 16 underwent radiation therapy and chemotherapy (intravenous infusion). Radiation doses to the involved area were 22-54 Gy (median dose, 49 Gy). RESULTS: The 5- and 10-year cause-specific survival rates were 91% and 73%, respectively. The 5- and 10-year disease-free survival rates were 83% and 59%, respectively. Eight patients developed recurrent disease: six at the local site, one in the cervical nodes, and one in the small intestine. Five of the six patients with local recurrence received less than 50 Gy. Four of the six patients developed recurrent disease in the treated area; the other two patients developed marginal recurrences. Prognostic factors such as age, sex, maximum tumor size, and lactate dehydrogenase level were of limited value. CONCLUSION: The most common recurrence site was the local site. To improve the local control rate, the involved area should be treated with high-dose radiation therapy. The clinical results did not demonstrate the usefulness of combination chemotherapy for stage IE nasal lymphoma.


This article has been cited by other articles:


Home page
 Ann OncolHome page
B.-S. Kim, D.-W. Kim, S.-A. Im, C. W. Kim, T.-Y. Kim, S.-S. Yoon, D. S. Heo, Y.-J. Bang, S. Park, B. K. Kim, et al.
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
Ann. Onc., August 5, 2008; (2008) mdn551v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y.-X. Li, B. Yao, and J. Jin
In Reply:
J. Clin. Oncol., June 10, 2006; 24(17): 2685 - 2686.
[Full Text] [PDF]

Home page
 JCOHome page
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al.
Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma
J. Clin. Oncol., January 1, 2006; 24(1): 181 - 189.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-Y. You, K.-H. Chi, M.-H. Yang, C.-C. Chen, C.-H. Ho, W.-K. Chau, H.-C. Hsu, J.-P. Gau, C.-H. Tzeng, J.-H. Liu, et al.
Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan
Ann. Onc., April 1, 2004; 15(4): 618 - 625.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 1997 by the Radiological Society of North America.